- Evolent Health looks set to deliver double-digit organic growth over the coming 12 months, with a new strategy that aligns with macroeconomic crosscurrents.
- The company has added 8 new partnerships this year, and commercial health plans now make up 20% of total sales.
- Margin pressures have been alleviated with the updated model, and management see further margin expansion in 2021.
- Shares are trading in line with peers, and based on conservative multiples, we see a price target of $18 over the next 12 months.
For further details see:
Evolent Health Key Takeouts: Valuation In Line With Peers, 8 New Partnerships YTD